Aptinyx (APTX) Lowered to “Hold” at Zacks Investment Research

Aptinyx (NASDAQ:APTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “

APTX has been the subject of several other reports. Cantor Fitzgerald reissued a “buy” rating on shares of Aptinyx in a report on Tuesday, April 30th. BMO Capital Markets reissued an “outperform” rating on shares of Aptinyx in a report on Friday, March 22nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $12.95.

Shares of APTX stock opened at $3.48 on Monday. The firm has a market cap of $117.80 million and a price-to-earnings ratio of -1.32. Aptinyx has a 1-year low of $3.27 and a 1-year high of $32.25.

Aptinyx (NASDAQ:APTX) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). The company had revenue of $0.89 million for the quarter, compared to analyst estimates of $1.00 million. Aptinyx had a negative return on equity of 37.53% and a negative net margin of 1,166.40%. Sell-side analysts predict that Aptinyx will post -2.18 earnings per share for the current year.

In other Aptinyx news, Director Henry O. Gosebruch purchased 100,000 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The stock was acquired at an average cost of $3.86 per share, with a total value of $386,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 8.47% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Great West Life Assurance Co. Can acquired a new position in shares of Aptinyx in the 4th quarter valued at about $40,000. Gabelli Funds LLC acquired a new position in shares of Aptinyx in the 1st quarter valued at about $44,000. Dimensional Fund Advisors LP acquired a new position in shares of Aptinyx in the 1st quarter valued at about $57,000. Legal & General Group Plc acquired a new position in shares of Aptinyx in the 3rd quarter valued at about $58,000. Finally, Alambic Investment Management L.P. acquired a new position in shares of Aptinyx in the 1st quarter valued at about $87,000. 61.39% of the stock is owned by institutional investors and hedge funds.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Article: Strike Price

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.